aTyr Pharma Inc. (ATYR) — RQD Stock Rating Cockpit

Per the Roarable RQD rating, ATYR scores 45 out of 100, a letter grade of D, with the verdict "Roarable Sell — Underperform / Distribution Warning." The five pillars are:

• Fundamental Cash Engine: 9 / 20. Per the Roarable RQD rating, this pillar reflects ROIC of -35% and an FCF yield of 0%. For an investor, this means the business is not currently generating returns on capital or free cash flow to support its valuation from operations.
• Whale 13F Flow: 14 / 20. Per the Roarable RQD rating, this pillar captures institutional accumulation and options positioning. This is the highest-scoring pillar, which suggests some institutional interest, though the source data does not itemize the holders behind it.
• Insider Conviction: 3 / 20. Per the Roarable RQD rating, this pillar reflects SEC Form 4 and Congressional PTR cluster flow. The low score indicates weak insider signal in the sources.
• Macro Regime Fit: 12 / 20. Per the Roarable RQD rating, beta is 1.0 with sector sensitivity noted. This is a moderate score, with no further macro detail in the sources.
• Forensic Balance Sheet: 7 / 20. Per the Roarable RQD rating, the Altman Z-Score is 2.5, the Piotroski F-Score is 2/9, and Debt/Equity is 0.5. The weak Piotroski reading and the modest Z-Score point to balance sheet fragility.

For a prospective investor evaluating the stock today, the upside drivers are limited to the institutional-flow and news-catalyst narrative. The valuation tradeoff is stark: a $13.5M market capitalization against negative operating income of -$77.6M in FY 2025 means the market is pricing a company whose operating losses far exceed its size. The 52-week range of $0.1 to $5.43 shows the price has moved widely, and the current price of 5.37 sits near the top of that range. Investors should weigh the attention in recent news against the weak cash generation and forensic signals.

aTyr Pharma Inc. is a NASDAQ-listed issuer in the Health Care sector, operating in the Biotechnology: Biological Products (No Diagnostic Substances) industry. Per the company profile, its market capitalization is $0.0B. Per the recent news wire, the company's experimental protein reduced lung fibrosis in a model, and aTyr expects to move it into testing in 2027. Revenue is minimal, reported at $0.2M for FY 2025, and the source data does not describe the customer base or the specific commercial model beyond this.

Per the SEC financials, net losses widened from $-50.4M in FY 2023 to $-74.1M in FY 2025, while revenue declined from $0.4M to $0.2M. Per the market data, operating margin and net margin are each -60%, gross margin is 0%, and ROIC is -35%. Per the Roarable RQD rating, the Altman Z-Score is 2.5 and the Piotroski F-Score is 2/9, indicating weak forensic health. Debt/Equity is 0.5 per the RQD forensic pillar. Cash declined from $11.1M to $10.7M across FY 2024 to FY 2025.

• Price target and upside (GREEN, CATALYST): A TradingView report indicates a 12-month price target raised to $3.2, implying 1757% upside. This is a bullish sell-side or media framing that the sources do not independently verify.
• Market coverage (YELLOW, MARKET WIRE): Simply Wall St, Yahoo Finance Canada, and GuruFocus items cover stock analysis, seasonal returns, and institutional positioning. GuruFocus notes that Federated Hermes trimmed its aTyr stake, a distribution signal.
• Reverse stock split (YELLOW, MARKET WIRE): Investing.com reports a 1-for-40 reverse stock split effective October 28. Per the source, this is a material structural event affecting share count and price presentation.
• Pipeline (YELLOW, MARKET WIRE): Stock Titan reports the experimental protein reduced lung fibrosis in a model, with testing expected in 2027.
• Risk watch items: The reverse split, the institutional trim, and the negative operating margin are the primary items to monitor.
• Butterfly graph: Not available in source data beyond the absence of linked supply-chain nodes and proprietary signals.

Per the Butterfly Supply-Chain Graph, the supply chain is listed as NONE, with no butterfly links and no proprietary signals. Upstream and downstream dependencies, sector correlations, and second-order bottlenecks are therefore not available in source data. The only sector context is the Health Care classification and the Biological Products industry label. A prospective investor should note that the pipeline timeline (testing in 2027) implies the company's value depends on future clinical progress that the sources do not map to any partners, suppliers, or customers.

• What is the company's cash runway given $10.7M in FY 2025 cash against a $-62.1M free cash flow outflow?
• What financing or dilution events are implied by the 1-for-40 reverse split, and what drove the decision?
• What are the specific holders behind the RQD whale 13F flow score, and what is the direction of recent institutional changes?
• Which assets, trials, or partners underpin the lung fibrosis program, and what are its regulatory milestones beyond the 2027 testing reference?
• What explains the zero Debt figure gap and the N/A debt values, which leave the leverage picture incomplete?